A Phase 1b, 2-Part, Investigator- and Participant-Blind, Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LY3532226 in Participants With Type 2 Diabetes Mellitus
Latest Information Update: 22 Nov 2024
At a glance
- Drugs Dulaglutide (Primary) ; Macupatide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Therapeutic Use
- Sponsors Eli Lilly and Company
Most Recent Events
- 28 Mar 2024 Status changed from active, no longer recruiting to completed.
- 04 Jan 2024 Planned End Date changed from 13 Jan 2024 to 12 Jan 2024.
- 04 Jan 2024 Planned primary completion date changed from 24 Dec 2023 to 12 Jan 2024.